{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:20:09Z","timestamp":1771273209460,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.coph.2023.102426","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T23:11:45Z","timestamp":1704064305000},"page":"102426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Human experience and efficacy of omidenepag isopropyl (Eybelis\u00ae; Omlonti\u00ae): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug"],"prefix":"10.1016","volume":"74","author":[{"given":"Najam A.","family":"Sharif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2023.102426_bib1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","article-title":"Glaucoma","volume":"377","author":"Quigley","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2023.102426_bib2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmol Times"},{"key":"10.1016\/j.coph.2023.102426_bib3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2023.102426_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053805","article-title":"Time trends, associations and prevalence of blindness and vision loss due to glaucoma: an analysis of observational data from the Global Burden of Disease Study 2017","volume":"12","author":"Sun","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.coph.2023.102426_bib5","first-page":"1","article-title":"Emerging drugs for the treatment of glaucoma: a review of phase II & III trials","author":"Kaplan","year":"2022","journal-title":"Expet Opin Emerg Drugs"},{"key":"10.1016\/j.coph.2023.102426_bib6","first-page":"22","article-title":"Ocular hypertension and glaucoma: a review and current perspectives","volume":"2","author":"Sharif","year":"2017","journal-title":"Internet J Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_sref7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.729249","article-title":"Therapeutic drugs and devices for tackling ocular hypertension and glaucoma, and need for neuroprotection and cytoprotective therapies","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2023.102426_bib8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2023.102426_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/02713683.2011.593725","article-title":"A\u00a0phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension","volume":"36","author":"Schachar","year":"2011","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.coph.2023.102426_bib12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/bph.14327","article-title":"Discovery, characterization and clinical utility of prostaglandin agonists for treatment of glaucoma","volume":"176","author":"Klimko","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"53 Suppl1","key":"10.1016\/j.coph.2023.102426_bib13","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","article-title":"Side effects associated with prostaglandin analog therapy","author":"Alm","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib14","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0039-6257(02)00293-X","article-title":"Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist","volume":"47","author":"Hellberg","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2174\/138945010791591278","article-title":"Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action","volume":"11","author":"Sharif","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.coph.2023.102426_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ddr.21174","article-title":"FR-190997, a non-peptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys","volume":"75","author":"Sharif","year":"2014","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.coph.2023.102426_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajo.2018.05.015","article-title":"A\u00a0randomized, controlled Phase I\/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma","volume":"192","author":"Stacy","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.exer.2009.05.002","article-title":"Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models","volume":"89","author":"Prasanna","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2023.102426_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exer.2016.04.020","article-title":"ATP sensitive potassium channel openers: a new class of ocular hypotensive agents","volume":"158","author":"Roy Chowdhury","year":"2017","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2023.102426_sref20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1089\/jop.2021.0077","article-title":"Phase 2b, randomized, 3-month, dose-finding study of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: the ANGEL Study","volume":"38","author":"Wirta","year":"2022","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/jop.2004.20.489","article-title":"Molecular pharmacology of the DP\/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes","volume":"20","author":"Sharif","year":"2004","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_bib22","first-page":"513","article-title":"Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue","volume":"23","author":"Stjernschantz","year":"1995","journal-title":"Adv Prostag Thromb Leukot Res"},{"key":"10.1016\/j.coph.2023.102426_bib23","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1167\/iovs.08-2800","article-title":"Effects of prostanoid EP agonists on mouse intraocular pressure","volume":"50","author":"Saeki","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_bib24","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1167\/iovs.05-1627","article-title":"The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey","volume":"47","author":"Nilsson","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exer.2011.02.015","article-title":"Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma","volume":"93","author":"Prasanna","year":"2011","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2023.102426_bib26","article-title":"Topical medication therapy for glaucoma and ocular hypertension","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2023.102426_bib27","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1021\/acs.jmedchem.8b00808","article-title":"Identification of a selective, non-prostanoid EP2 Receptor agonist for the treatment of glaucoma: omidenepag and its prodrug omidenepag isopropyl","volume":"61","author":"Iwamura","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.coph.2023.102426_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1167\/iovs.17-22745","article-title":"Pharmacologic Characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent","volume":"59","author":"Kirihara","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/jop.2017.0146","article-title":"Effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys","volume":"34","author":"Fuwa","year":"2018","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"issue":"Suppl1","key":"10.1016\/j.coph.2023.102426_bib30","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","article-title":"Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction","volume":"53","author":"Toris","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/jop.2019.0079","article-title":"Effects of the selective EP2 receptor agonist omidenepag on adipocyte differentiation in 3T3-L1 cells","volume":"36","author":"Yamamoto","year":"2020","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/108076801750125658","article-title":"Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells","volume":"17","author":"Crider","year":"2001","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_bib33","first-page":"1475","article-title":"Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues","volume":"43","author":"Schlotzer-Schrehardt","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_bib34","first-page":"3182","article-title":"Detection of prostaglandin EP(1), EP(2), and FP receptor subtypes in human sclera","volume":"42","author":"Anthony","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_bib35","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.bbrc.2005.10.051","article-title":"Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42\/44 mitogen-activated protein kinases","volume":"338","author":"Rosch","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coph.2023.102426_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/exer.1996.0119","article-title":"Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species","volume":"63","author":"Yousufzai","year":"1996","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2023.102426_bib37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/10807680260362678","article-title":"Production of prostaglandin e(2) by iridial melanocytes exposed to latanoprost acid, a prostaglandin F(2 alpha) analogue","volume":"18","author":"Bergh","year":"2002","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_bib38","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1038\/s41598-021-83713-z","article-title":"Mechanical stretch induces Ca(2+) influx and extracellular release of PGE2 through Piezo1 activation in trabecular meshwork cells","volume":"11","author":"Uchida","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2023.102426_bib39","first-page":"3195","article-title":"Prostanoid-induced relaxation of precontracted cat ciliary muscle is mediated by EP2 and DP receptors","volume":"33","author":"Chen","year":"1992","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_bib40","first-page":"2515","article-title":"Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide","volume":"35","author":"Wiederholt","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_bib41","first-page":"1188","article-title":"Characterization of ciliary muscle relaxation induced by various agents in cats","volume":"36","author":"Goh","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_bib42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1006\/exer.1996.0224","article-title":"Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle","volume":"64","author":"Krauss","year":"1997","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2023.102426_bib43","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1167\/iovs.08-3127","article-title":"Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel","volume":"50","author":"Dismuke","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_bib44","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1167\/iovs.09-5072","article-title":"Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling","volume":"51","author":"Ellis","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2023.102426_sref45","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/IJG.0000000000001221","article-title":"Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Aihara","year":"2019","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.coph.2023.102426_bib46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/jop.2019.0044","article-title":"Pharmacokinetics, safety, and intraocular pressure-lowering profile of omidenepag isopropyl, a selective, non-prostaglandin, prostanoid EP2 receptor agonist, in healthy Japanese and Caucasian volunteers (Phase I Study)","volume":"35","author":"Aihara","year":"2019","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_sref47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","article-title":"Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase 3 AYAME study","volume":"220","author":"Aihara","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib48","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s10384-020-00748-x","article-title":"Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-\/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study","volume":"64","author":"Aihara","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_sref49","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s10384-021-00868-y","article-title":"Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study","volume":"65","author":"Aihara","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib50","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/jop.1998.14.293","article-title":"Prostaglandin-stimulated adenylyl cyclase activity via a pharmacologically-defined EP2 receptor in human NPE cells","volume":"14","author":"Crider","year":"1998","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_sref51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/jop.2020.0071","article-title":"Additive intraocular pressure-lowering effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, combined with existing antiglaucoma agents in conscious ocular normotensive monkeys","volume":"37","author":"Fuwa","year":"2021","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_bib52","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/jop.2019.0041","article-title":"Antiglaucoma EP2 agonists: a long road that led somewhere","volume":"35","author":"Woodward","year":"2019","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_bib53","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bph.14525","article-title":"The affinity, intrinsic activity and selectivity of a structurally novel EP2 receptor agonist at human prostanoid receptors","volume":"176","author":"Coleman","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2023.102426_bib54","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/bjophthalmol-2020-317762","article-title":"The role of EP2 receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1","volume":"105","author":"Bertrand","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/IJG.0000000000001836","article-title":"A\u00a0Randomized Phase 2 trial comparing omidenepag isopropyl 0.002% once and twice daily in subjects with primary open-angle glaucoma or ocular hypertension (SPECTRUM-6)","volume":"30","author":"Olander","year":"2021","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.coph.2023.102426_bib56","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/02713689808951229","article-title":"Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?","volume":"17","author":"Lind\u00e9n","year":"1998","journal-title":"Curr Eye Res"},{"issue":"Suppl 4","key":"10.1016\/j.coph.2023.102426_bib57","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1016\/S0039-6257(01)00219-3","article-title":"Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure","volume":"45","author":"Sherwood","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95768-z","article-title":"Effects of selective EP2 receptor agonist, omidenepag, on trabecular meshwork cells, Schlemm's canal endothelial cells and ciliary muscle contraction","volume":"11","author":"Nakamura","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2023.102426_sref59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0280331","article-title":"Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human\u00a0trabecular meshwork cells","volume":"18","author":"Kumon","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2023.102426_sref60","article-title":"FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma","volume":"299","author":"Sharif","year":"2023","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2023.102426_bib61","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.bbamcr.2016.06.008","article-title":"Prostaglandin EP2 receptor signaling protects human trabecular meshwork cells from apoptosis induced by ER stress through down-regulation of p53","volume":"1863","author":"Kalouche","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.coph.2023.102426_bib62","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1167\/iovs.15-17693","article-title":"Activation of prostaglandin FP and EP2 receptors differently modulates myofibroblast transition in a model of adult primary human trabecular meshwork cells","volume":"57","author":"Kalouche","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 2","key":"10.1016\/j.coph.2023.102426_bib63","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0039-6257(97)80020-3","article-title":"The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color","volume":"41","author":"Wistrand","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib64","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ceo.12163","article-title":"Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost","volume":"42","author":"Kucukevcilioglu","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib65","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s40265-018-1016-1","article-title":"Omidenepag isopropyl ophthalmic solution 0.002%: first global approval","volume":"78","author":"Duggan","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2023.102426_sref66","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s12325-022-02069-6","article-title":"Efficacy and safety of omidenepag isopropyl 0.002% ophthalmic solution: a retrospective analysis of real-world data in Japan","volume":"39","author":"Miki","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.coph.2023.102426_bib67","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s12325-021-02035-8","article-title":"Interim results of post-marketing observational study of omidenepag isopropyl for glaucoma and ocular hypertension in Japan","volume":"39","author":"Nakazawa","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.coph.2023.102426_bib68","doi-asserted-by":"crossref","DOI":"10.1097\/IJG.0000000000002321","article-title":"Omidenepag isopropyl in latanoprost low\/non-responders with primary open-angle glaucoma or ocular hypertension: a phase 3, non-randomized, two-phase, open-label study","author":"Panarelli","year":"2023","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.coph.2023.102426_sref69","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajo.2021.12.011","article-title":"Periocular adverse reactions to omidenepag isopropyl","volume":"237","author":"Inoue","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_bib70","article-title":"Evaluation of patterns and correlations of the degree of conjunctival hyperemia induced by omidenepag isopropyl 0.002% and ripasudil 0.4","volume":"12","author":"Terao","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2023.102426_sref71","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2147\/OPTH.S340386","article-title":"Efficacy and patient tolerability of omidenepag isopropyl in the treatment of glaucoma\u00a0and ocular hypertension","volume":"16","author":"Matsuo","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.coph.2023.102426_sref72","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/jop.2020.0003","article-title":"The antiglaucoma agent and EP2 receptor agonist omidenepag does not affect eyelash growth in mice","volume":"36","author":"Esaki","year":"2020","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_bib73","doi-asserted-by":"crossref","DOI":"10.1089\/jop.2023.0058","article-title":"Clinical efficacy of omidenepag isopropyl for primary open-angle glaucoma, normal tension glaucoma, or ocular hypertension: a meta-analysis","author":"Kuo","year":"2023","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2023.102426_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109444","article-title":"Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness","volume":"232","author":"Sharif","year":"2023","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2023.102426_bib75","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3390\/ph16060791","article-title":"Recently approved drugs for lowering and controlling intraocular pressure to reduce vision loss in ocular hypertensive and glaucoma patients","volume":"16","author":"Sharif","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.coph.2023.102426_bib76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/1673-5374.343887","article-title":"Neuroaxonal and cellular damage\/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors","volume":"18","author":"Sharif","year":"2023","journal-title":"Neural Regen Res"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489223000814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489223000814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:58:55Z","timestamp":1761461935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489223000814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":76,"alternative-id":["S1471489223000814"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2023.102426","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human experience and efficacy of omidenepag isopropyl (Eybelis\u00ae; Omlonti\u00ae): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2023.102426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102426"}}